State Street Corp Sigilon Therapeutics, Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.48 - $0.86 $15,600 - $27,950	-32,500 Reduced 44.04%	41,300 $21,000
Q2 2022 Aug 15, 2022	SELL	$0.74 - $1.64 $189,936 - $420,940	-256,671 Reduced 77.67%	73,800 $61,000
Q1 2022 May 16, 2022	BUY	$1.24 - $3.03 $86,380 - $211,075	69,662 Added 26.71%	330,471 $486,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $87,947 - $208,959	34,088 Added 15.04%	260,809 $720,000
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $434,455 - $1.04 Million	98,293 Added 76.54%	226,721 $1.28 Million
Q2 2021 Aug 16, 2021	BUY	$9.15 - $20.17 $476,660 - $1.05 Million	52,094 Added 68.24%	128,428 $1.38 Million
Q1 2021 May 17, 2021	BUY	$18.76 - $40.91 $1.43 Million - $3.12 Million	76,334 New	76,334 $1.71 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.